WHO Releases PFAS Landscape Review (Does Not Meet AIMEILI News Admission Criteria)

Key Summary

The World Health Organization (WHO) has published a landscape review on per- and polyfluoroalkyl substances (PFAS) via oral ingestion and their health effects. The content falls within the scope of chemical safety and public health and is not directly related to medical devices. It does not meet the admission criteria for this column and is therefore not published.

Source and Applicability

• Source organization: WHO Publications – Medical Devices
• Original publication date: 30 July 2026
• Recorded by this site: 2026-07-30T07:44:12.912Z
• Published by this site: 2026-07-31 11:00
• Article source: WHO Publications – Medical Devices

This article is compiled from publicly available information from WHO Publications – Medical Devices. Source: https://www.who.int/publications/i/item/9789240123106. Specific requirements are subject to the latest official release by the regulatory authority.

Full Translation of the Original Core Content

The World Health Organization (WHO) commissioned a landscape review to systematically collect and evaluate existing data sources on PFAS exposure and related health effects. The objective was to identify priority PFAS and health effect categories for further in-depth assessment. PFAS exposure data sources from environmental studies, human biomonitoring studies, and health effects were combined and assessed to form a comprehensive database on PFAS exposure and health effects (see supplementary tables). The review identified 77 PFAS from the exposure evidence base and 66 PFAS from the health effects evidence base. The landscape review also included the development of a prioritization framework to rank PFAS and health effect categories.

This report provides a high-level overview of the landscape review. It recommends further assessment of 18 PFAS and 6 health effect categories. The findings lay the foundation for more detailed systematic evidence reviews to support the development of health-based PFAS values.

Related documents: Supplementary Table 1 is the database of PFAS exposure information included in the landscape review; Supplementary Table 2 is the database of PFAS health effects information included in the landscape review.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI Viewpoint

The original text addresses environmental exposure and health effect assessment of PFAS and falls within WHO's chemical safety and public health work. It is not directly related to medical device registration, classification, technical files, clinical evaluation, labeling, quality management systems, or post-market surveillance. Under the admission criteria for this column, food, contaminant, or general public health content of this kind should not be included in the news feed. Therefore, AIMEILI's regulatory team does not provide a specific regulatory interpretation for this item, and publication is not recommended.

What This Means for Medical Device Companies

From the perspective of international medical device registration practice, information such as this from WHO Publications – Medical Devices should not be read merely as general industry news. Companies should first determine whether it concerns regulatory policy, guidance standards, product approvals, recall safety, quality systems, or post-market regulatory information, because different types of information correspond to different internal actions. If a company is advancing a related market registration project, it should add the update to its target-market regulatory tracking table and confirm whether it affects product classification, registration pathway, applicant entity, local agent responsibilities, or certificate maintenance arrangements.

For Chinese medical device companies, the direct impact of this WHO PFAS landscape review is usually reflected in document consistency and evidence chain management. The key is to convert the news into executable compliance actions: confirm whether it involves similar products, similar technology routes, or similar risk points; check whether existing materials still support target-market requirements; and, where necessary, update risk management, performance verification, clinical evaluation, labels and instructions for use, distributor communication, and post-market surveillance records.

What Documents Should Companies Check?

Companies should prioritize checking the product's intended use, classification basis, ISO 13485 quality management system certificates, risk management files, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, and existing registration certificates.

Common Risks

Common risks include unclear classification judgments, incomplete evidence chains, non-localized labels and instructions for use, unclear responsibilities of authorized representatives, and insufficient post-market maintenance arrangements.

Recommended Actions

At the implementation level, AIMEILI recommends three actions: first, record the official source link, publication date, applicable product scope, and potentially affected areas in the regulatory tracking log; second, have regulatory, quality, R&D, and sales teams jointly determine whether labels, instructions for use, clinical evaluation, risk management, or test reports need to be updated; third, if the company has already marketed products locally or has submitted a registration application, it should simultaneously assess whether local agents, importers, distributors, and after-sales teams need to take communication, change, supplementary explanation, or post-market surveillance measures.

The value of this type of news is not simply knowing what a regulatory authority has published, but converting public information into executable compliance actions. For companies preparing for multi-country registration, particular attention should be paid to the boundaries of document reuse across markets: the same set of CE, FDA, NMPA, ISO 13485, or MDSAP documents may serve as core evidence in one country, while in another country they may require localized explanations, language labeling, authorized representative documents, or post-market maintenance plans. AIMEILI recommends that companies conduct a brief document gap review after each important regulatory update to avoid being caught off guard during subsequent corrections, changes, or certificate renewals.

FAQ

Can the WHO PFAS landscape review be used directly as a basis for submission? No. This article is intended for preliminary understanding and project assessment. Formal submissions must still be based on the latest requirements of the target country's regulatory authority, product classification conclusions, and the company's actual documentation.

What should companies do first after seeing such an update? It is recommended to first conduct a document gap assessment to confirm whether the update affects the registration pathway, technical files, labeling, quality system, or post-market maintenance.

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as auxiliary references for judgment.

Applicability boundaries: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.